secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0000899923-25-000072
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics closes $200M credit facility with OrbiMed; $125M funded
-----------------------------------------------------------------------

- Five-year senior secured term loan; $125M funded at closing, $75M delayed draw available through June 2027.
- Interest rate of one-month SOFR + 6.50%, with a 2.50% SOFR floor; matures July 31, 2030.
- Proceeds for working capital, general corporate purposes, and refinancing existing ABL facility.
- Credit facility is secured by substantially all assets of Myriad and its subsidiaries.
- Company now has access to over $200M in capital (including cash) to support growth strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000072/0000899923-25-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000072/mygn-20250731.htm
  HTML page:      https://secwatch.observer/filing/0000899923-25-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer